AZNCF News and Press, AstraZeneca Plc From 01/28/23

Summary FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns. If the deal closes, the stock should rise 30%; if it fails, FSTX still has very valuable assets. The only r...

Summary Wall Street has gone downgrade happy on Pfizer in January, loudly complaining the end of the pandemic has arrived. What brokerage analysts are failing to appreciate is Pfizer now has the strongest balance sheet and free cash flow setup in Big Pharma. If you like cash holding...

Summary Argenx caught a strong bid in FY22 on the back of advancements in its Efgartigimod [Vyvgart] pipeline for Myasthenia Gravis. Demand began to fade rolling into the new year, with heavy outflows across the 3-months to-date. The company reported strong results in its Vyvgart se...

Summary As a leader in various therapeutic areas, the company's total revenue was $7,042 million in the third quarter of 2022, up 12.5% quarter-on-quarter. Gilead will be required to make royalties of 3% on future sales of Biktarvy and bictegravir-containing medicines up to the 4th quar...

The following slide deck was published by AstraZeneca PLC in conjunction with this event. For further details see: AstraZeneca (AZN) Presents At 41st Annual Healthcare Conference - Slideshow

Summary Drug addiction is on the rise but so are treatments for it, like those provided by Indivior for opioid usage. With growing revenues and exceptional margins, its price is rising. Its price is already up by 55% over the year, and going by the fact that its P/E is lower than that f...

Summary We may not be at the end credits for COVID-19 virus. Shares of Vaxxinity, Inc., like most biotechs, have plummeted over the past year due to unprecedented market headwinds, both macroeconomic and geopolitical. In the meantime, the company has been taking care of its COVID-19...

Summary AstraZeneca is acquiring CinCor Pharma for $26 per share and an interesting CVR. The milestone appears easy enough to achieve although the company just had a phase 2 setback. The market values the CVR at $3.21, assuming the deal closes. The CVR pays out $10 if the milest...

Summary Dividend growth stocks can contribute significantly to increasing your additional income in the form of dividends year over year. In this article I will present 3 companies that I currently consider to be attractive, particularly due to their strong competitive advantages and cu...

Summary The pipeline is the heart of a drug discovery company. As such, analyzing the health of a pipeline can lead to suggestions about future performance. This article will analyze the 10 largest pharmaceuticals and determine where the strongest pipelines lie. Introducti...